#USA #Warren #Rare Diseases #NORD #Regal Intel

Regal Intel Secures Important Funding for Rare Disease Research

In a significant advancement for rare disease research, Regal Intel, Inc., a 501(c)(3) nonprofit organization based in Warren, New Jersey, has recently received two seed grants totaling $65,000. These funds are allocated to study the outcomes of patients affected by epidermodysplasia verruciformis (EV) and Peutz-Jeghers syndrome (PJS) under specific surveillance guidelines. Both grants were facilitated through the National Organization for Rare Disorders (NORD), which supports innovative research aimed at improving patient care in conditions that lack extensive empirical evidence.

Background of the Research

The conditions being studied, EV and PJS, are classified as ultra-rare. Current estimates suggest that the prevalence of EV is less than one case per million, with recorded instances in the literature numbering fewer than 200. Meanwhile, PJS affects approximately one to nine individuals per million. The rarity of these diseases poses challenges for conducting traditional statistical studies, often leaving experts reliant on anecdotal evidence and expert opinion when developing surveillance protocols.

The Study on Epidermodysplasia Verruciformis (EV)

Epidermodysplasia verruciformis is a lifelong genetic dermatological condition resulting from mutations in the TMC6 or TMC8 genes, exacerbated by persistent human papillomavirus (HPV) infections. Patients face a notably elevated lifetime risk of non-melanoma skin cancers, estimated to range from 30% to 50%. Despite internationally recognized guidelines recommending rigorous dermatological surveillance for these patients, the lack of concrete data regarding real-world treatment outcomes has made it challenging to design effective monitoring strategies. The research aims to utilize existing clinical records to evaluate long-term cancer-free survival rates among patients with EV.

The Study on Peutz-Jeghers Syndrome (PJS)

Peutz-Jeghers syndrome is a hereditary cancer syndrome that arises from germline mutations in the STK11 gene. This condition is noted for its nearly complete penetrance, meaning most patients develop issues, though the type and timing of these complications can differ greatly among individuals. Previous studies have produced mixed results regarding the severity of disease based on specific genetic variants, leading to uncertainty in the recommendations for patient surveillance. This new study will correlate specific STK11 variants with the age of onset for serious complications, including bowel obstructions and subsequent cancer risk, thus offering potential new insights into individualized care.

Innovative Data Analysis

Both research initiatives will implement NeuSymbol™, a cutting-edge platform developed by Regal Intel for analyzing longitudinal patient data. This platform enables doctors and researchers to conduct thorough evaluations of clinical records while ensuring de-identification of patient information to comply with HIPAA regulations. By doing so, it helps to maintain patient privacy, allowing for broader and more effective analysis. Sanjay Ahuja, Ph.D., the Chief Science Officer at Regal Intel, will lead these ambitious projects, underscoring the organization’s commitment to leveraging real-world evidence to inform better healthcare practices.

The Importance of these Grants

According to Pamela Gavin, CEO of NORD, these grants signify crucial investments into research for conditions often overlooked by major pharmaceutical companies. “Fewer than 5% of rare diseases have an FDA-approved therapy, and early funding is crucial to develop these ideas into tangible progress,” she notes. Both research endeavors reflect a shift towards utilizing data that already exists in clinical settings to inform guideline development and improve patient outcomes.

Conclusion

As Regal Intel embarks on these significant studies, it represents a turning point for understanding the real impacts of clinical guidelines on ultra-rare diseases. With a rich history of supporting rare disease research, NORD continues to highlight the necessity of such funding to make strides in areas long neglected by the healthcare establishment. The outcomes of these studies could prove transformative for patients struggling with EV and PJS, making stringent surveillance protocols safer and more personalized based on concrete evidence derived from real clinical experiences.